Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Leukemia 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Meningioma 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Exanthema 1 Endometrial Neoplasms 1 Disease Progression 1 Diarrhea 1 Chondrosarcoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Fulvestrant 5 olaparib 4 Letrozole 4 Aromatase Inhibitors 3 Anastrozole 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Goserelin 2 FCN-437c 2 Capecitabine 2 talazoparib 1 sonidegib 1 ribociclib 1 neratinib 1 liposomal doxorubicin 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1 Vinorelbine 1 Trastuzumab 1 Taxes 1 Tablets 1 Safety 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡